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Background: Darpp-32 and t-Darpp are expressed in several forms of breast cancer. Both are transcribed from the gene
PPP1R1B via alternative promoters. In humans, Darpp-32 is expressed in both normal and malignant breast tissue,
whereas t-Darpp has only been found in malignant breast tissue. The exact biological functions of these proteins in the
breast are not known. Although Darpp-32 is a well known regulator of neurotransmission, its role in other tissues and in
cancer is less well understood. t-Darpp is known to increase cellular growth, inhibit apoptosis and contribute to
acquired drug resistance. The use of transgenic mouse mammary tumor models to study Darpp-32 and t-Darpp
in breast cancer in vivo has been limited by a lack of knowledge regarding t-Darpp expression in mice, in both
normal and malignant tissue.
Methods: We used RT-PCR and Western analysis to investigate Darpp-32 and t-Darpp levels in normal and malignant
mouse mammary tissue. To determine if Darpp-32 and t-Darpp play a direct role in mammary tumor development,
Ppp1r1b gene knockout mice and wild-type mice were crossed with a mouse mammary tumor model. Tumor growth
and metastasis were examined. Differences between groups were determined by the two-tailed Student’s t-test.
Results: We found that Darpp-32 was expressed in normal mouse mammary tissue and in some breast tumors, whereas
t-Darpp was found exclusively in tumors, with t-Darpp usually expressed at equal or higher levels than Darpp-32. Ppp1r1b
knockout in MMTV-PyMT transgenic tumor mice resulted in a decrease in tumor growth.
Conclusions: The shift in expression from Darpp-32 to t-Darpp during mouse mammary tumorigenesis is reminiscent of
the expression patterns observed in humans and is consistent with a role for t-Darpp in promoting cell growth and
Darpp-32 in inhibiting cell growth. Decreased tumor growth in Ppp1r1b knockout mice also suggests that t-Darpp plays
a direct role, predominant to Darpp-32, in mammary tumor development. These results indicate that transgenic mouse
mammary tumor models might be valuable tools for future investigation of Darpp-32 and t-Darpp in breast cancer.
Keywords: PPP1R1B, Darpp-32, t-Darpp, MMTV-Neu, MMTV-PyMT, Breast cancer, TumorigenesisBackground
Darpp-32 (dopamine and cAMP regulated phosphopro-
tein of 32 kD) is well known for its primary role as an
integrator and regulator of neurotransmission [1]. It
has also recently been linked to cancer. El-Rifai and
colleagues were the first to find Darpp-32 and a trun-
cated variant, t-Darpp, in gastric carcinoma patient
samples [2]. Darpp-32 and t-Darpp expression has since
been identified in breast cancer as well as numerous
other types of malignancies [3].* Correspondence: skane@coh.org
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article, unless otherwise stated.The function of Darpp-32 in non-neuronal cells and
in cancer is not well understood. The majority of data
suggests that it has a growth inhibitory effect and a po-
tentially antagonistic relationship with t-Darpp [4-8].
The truncated t-Darpp protein lacks 36 amino acids at
the N-terminus, including a phosphorylation site crit-
ical to the function of Darpp-32 as a phosphatase in-
hibitor [2,9,10]. t-Darpp’s mechanism of action is not
known, but it has reported activity for increasing cell
growth, inhibiting apoptosis, and promoting drug re-
sistance in cancer cells [11-17].
Darpp-32 and t-Darpp are expressed from the gene
PPP1R1B (protein phosphatase 1, regulatory (inhibitor)
subunit 1B), utilizing unique transcription and translationd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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Figure 1 Darpp-32 and t-Darpp expression in normal mouse
mammary tissue. (A) Darpp-32 and t-Darpp protein levels were
measured by Western analysis. β–Actin levels were measured as a
loading control. Abdominal and inguinal mammary pads (#4/5 and
#9/10) were collected from wild-type FVB mice and from premalignant
transgenic mammary tumor mice. Mammary cells from two mice per
strain (two fat pads per mouse) were analyzed. The ratio of Darpp-32
to t-Darpp (Dp32:tDp) protein expression was calculated for each sample.
(B) Darpp-32 and t-Darpp RNA levels were measured by traditional
RT-PCR using isoform-specific primers. β–Actin levels were measured
as a loading control. RNA from a wild-type mouse brain was used as a
positive control. Mammary tissue samples were: 1) NMuMG mouse
mammary epithelial cell line, 2–5) four separate wild-type mammary
pads (non-dissociated) from two mice and 6) dissociated wild-type
mammary cells pooled from two mice.
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breast, Darpp-32 is expressed in both normal and malig-
nant tissue, whereas t-Darpp is typically found only in
breast adenocarcinomas [3,11,16]. The functional signifi-
cance of Darpp-32 and t-Darpp expression in breast can-
cer is not known, but the aberrant expression of these
proteins in cancer, as compared to the relatively low levels
observed in healthy tissue, indicates a possible role for
these proteins in tumor growth and progression.
To date, the role of Darpp-32 and t-Darpp in cancer has
been studied only in patient samples, cell lines, and xeno-
graft mouse models. Transgenic mouse tumor models such
as MMTV-Neu and MMTV-PyMT [18], in which mice de-
velop spontaneous mammary tumors, have heretofore been
unsuitable for the investigation of Darpp-32 and t-Darpp
due to the lack of published data on these proteins in
mouse mammary tissue. The existence of a truncated form
of Darpp-32 has not been reported for any cell type in mice,
although t-Darpp expression has been noted in the rat
brain [19]. The purpose of this study was to determine if
Darpp-32 and t-Darpp are expressed in mouse mammary
tissue and to see if their expression patterns are similar be-
tween humans and mice. Using a Ppp1r1b knockout
mouse, we also sought to determine the role of Darpp-32
and t-Darpp in breast tumorigenesis and progression.
Results
Darpp-32, but not t-Darpp, is expressed in normal mouse
mammary tissue
In humans, the full-length transcript encoding Darpp-32
is sometimes detected in normal, healthy epithelial tissue.
t-Darpp, on the other hand, is rarely expressed [3]. To de-
termine the expression patterns in normal mouse mam-
mary tissue, we collected multiple mammary pads from
wild-type mice and from pre-malignant MMTV-Neu and
MMTV-PyMT transgenic mice. Because mouse mam-
mary pads are composed mostly of adipose tissue, the col-
lected tissue was enzymatically dissociated to isolate
mammary cells. Darpp-32 and t-Darpp protein (Figure 1A)
and mRNA (Figure 1B) levels were examined, using
mouse brain as a positive control. The majority (67%)
of normal mammary samples expressed Darpp-32 pro-
tein, whereas none expressed detectable levels of t-Darpp
(Figure 1A). Similar results were observed at the mRNA
level. All normal mammary samples, including both dis-
sociated and whole mammary pads as well as the nor-
mal mouse mammary epithelial cell line NMuMG,
expressed Darpp-32 mRNA but none expressed t-
Darpp mRNA (Figure 1B).
Darpp-32 and t-Darpp are expressed in mouse mammary
tumors
Both Darpp-32 and t-Darpp are overexpressed in human
breast cancers [3,11]. To determine if this is the case inmouse mammary tumors, we used two different trans-
genic models of mouse breast cancer, MMTV-Neu and
MMTV-PyMT. Tumors of different sizes and from dif-
ferent mammary pads were collected from both models.
Single tumors were collected from nine MMTV-Neu
mice whereas multiple tumors were collected from two
different MMTV-PyMT mice. Protein and mRNA were
collected from each tumor and analyzed for Darpp-32
and t-Darpp expression. In contrast to its expression in
the majority of normal mammary tissue samples, Darpp-
32 protein was seen in only 24% of mouse mammary tu-
mors. Conversely, t-Darpp, which was not detected in
normal tissue, was expressed at significant levels in 52%
of mammary tumors. There did not seem to be a correl-
ation between Darpp-32 or t-Darpp expression and
mouse model, tumor size or tumor location (Figure 2A).
Corresponding results were observed at the mRNA level,
with detectable levels of t-Darpp mRNA in the vast ma-
jority of tumors (Figure 2B). The ratio of Darpp-32 to
t-Darpp protein was significantly lower in the tumor
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Figure 3A). No significant difference in the protein ratios
was observed between tumor models (Figure 3B). These
results suggest a shift in protein levels from exclusively
Darpp-32 to predominantly t-Darpp during mouse mam-
mary malignant transformation, reminiscent of the ex-
pression patterns observed in human breast tissue.Knockout of Darpp-32 and t-Darpp leads to decreased
growth of spontaneous mouse mammary tumors
The previous experiments show that Darpp-32 and t-
Darpp are differentially expressed in normal and malig-
nant mouse mammary tissue. To determine if these
proteins have a direct effect on tumorigenesis and growth,
we crossed Ppp1r1b knockout mice with the MMTV-
PyMT mammary tumor model and examined the rate of
tumor initiation, growth and metastasis in the wild-type
(PyMT/Ppp1r1b+/+) and knockout (PyMT/Ppp1r1b-/-)
Ppp1r1b backgrounds. The way in which the Ppp1r1b
knockout mouse was engineered, with a neo cassette
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Figure 2 Darpp-32 and t-Darpp expression in transgenic mouse mam
MMTV-Neu mice. All ten MMTV-PyMT tumors were collected from two mice.
tumor location refers to the mammary pad from which the tumor origina
Western analysis. α–Tubulin and β–Actin were used as loading controls. T
calculated for each sample. (B) Darpp-32 and t-Darpp RNA levels were measu
primers. Data was normalized to β–Actin; mean ± standard deviation.[20], led to the knockout of both Darpp-32 and t-Darpp
expression in these mice. No Darpp-32 or t-Darpp pro-
tein was detected in normal tissue from Ppp1r1b-/- mice
(Ppp1r1b knockout in the absence of PyMT, Figure 4A-B),
nor tumor tissue from PyMT/Ppp1r1b-/- mice (Figure 4C-D).
To determine if the absence of Darpp-32 and t-Darpp
affected tumor growth, we monitored mice weekly from
8 to 20 weeks of age, both for the emergence of tumors
and for tumor volume. Control Ppp1r1b-/- mice did not
develop tumors in this timeframe, whereas tumors began
appearing in PyMT/Ppp1r1b-/- mice as early as 13 weeks.
PyMT/Ppp1r1b-/- mice did not show either significantly
earlier or delayed tumor formation relative to PyMT/
Ppp1r1b+/+ mice (Figure 5A). Similarly, the percentage of
mice that needed to be sacrificed early due to extensive
tumor burden (tumor volume >1500 mm3) was not chan-
ged by the absence of Darpp-32 and t-Darpp (Figure 5B).
A significant reduction in tumor volume, both in terms of
total tumor volume (p = 0.023, Figure 5C) and the volume
of the largest tumor per mouse (p = 0.021, Figure 5D), was
observed in PyMT/Ppp1r1b-/- mice at 20 weeks, com-


































mary tumors. Nine individual tumors were collected from nine different
Samples are arranged from smallest to largest (tumor volume) and the
ted. (A) Darpp-32 and t-Darpp protein levels were measured by
he ratio of Darpp-32 to t-Darpp (Dp32:tDp) protein expression was








































Figure 3 Differential ratio of Darpp-32 to t-Darpp in normal and tumor tissue. Darpp-32 and t-Darpp protein levels, from the Figures 1A and
2A Westerns, were quantified using ImageJ software and expressed as the ratio of Darpp-32 to t-Darpp. The ratio was calculated for (A) normal (n= 12)
and all malignant (n= 29) mouse mammary tissue (MMTV-Neu and MMTV-PyMT combined) and (B) MMTV-Neu (n= 9) versus MMTV-PyMT (n= 20)
tumor tissue. Shown are means ± standard deviation; *** p< 0.0001.
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other marker of proliferation and found no difference in
Ki67 staining between PyMT/Ppp1r1b+/+ and PyMT/
Ppp1r1b-/- mice (Figure 5E).
MMTV-PyMT is well known as a murine model of
tumor metastasis, with the majority of tumor bearing
mice developing metastasis to the lung [21]. Because
Darpp-32 has been shown to inhibit breast cancer cell
migration [5,6], we examined the possible effects of
Darpp-32 or t-Darpp on early tumor progression.
Vascularization is one of the first steps in the metastatic
cascade, with increased blood vessel formation facilitat-
ing the dissemination of primary tumor cells throughout
the body [22]. We therefore examined expression of the
vascular endothelial marker CD31 in tumors. We ob-
served no significant difference in the number of CD31-
positive endothelial cell clusters between PyMT/
Ppp1r1b+/+ and PyMT/Ppp1r1b-/- mice (Figure 5F).
To investigate possible effects on metastasis, we col-
lected lungs from 20-week-old tumor bearing mice and
looked for PyMT-positive metastatic nodules (Additional
file 1: Figure S1A). PyMT/Ppp1r1b-/- mice did not have
a statistically different number or size of metastases
compared with PyMT/Ppp1r1b+/+ mice, although there
might have been a pattern of fewer metastatic lung nod-
ules in the knockout mice (Figure 5G and Additional
file 1: Figure S1B). We also looked at Darpp-32 and t-
Darpp expression in PyMT/Ppp1r1b+/+ lung metasta-
ses. Since t-Darpp is a truncated version of Darpp-32,
there are no antibodies that will detect just t-Darpp
(and not Darpp-32) by immunohistochemistry. Instead,
we used an antibody that recognizes just Darpp-32 and
another that recognizes both Darpp-32 and t-Darpp,
and resulting staining patterns were examined by aveterinary pathologist. We saw no clear patterns in the
wild-type metastases to suggest under- or over-
expression of Darpp-32 or t-Darpp in metastases (data
not shown). Taken together, these results suggest that
Darpp-32 and t-Darpp are not directly involved in me-
tastasis in this mouse model (also see the Discussion).
Discussion
This is the first time that Darpp-32 and t-Darpp have
been examined in mouse mammary tissue and the first
evidence of t-Darpp expression in mice. Of greater inter-
est is the observation that expression seems to shift from
a predominance of Darpp-32 in normal mouse mam-
mary tissue towards a predominance of t-Darpp in ma-
lignant mammary tissue. This suggests that t-Darpp by
itself or the ratio of Darpp-32 to t-Darpp might be sig-
nificant in determining a cell’s tumorigenicity. We have
previously reported that Darpp-32 and t-Darpp appear
to have opposing functions in breast cancer cell lines,
with t-Darpp promoting cell survival and drug resistance
and Darpp-32 being growth inhibitory and reversing t-
Darpp’s effect [15]. This is consistent with the idea that
it is not just the overexpression of one protein or the
other, but rather their relative expression levels that de-
termine an overall growth or survival phenotype. This
might be a general phenomenon of normal versus malig-
nant tissue rather than a dose–response phenomenon,
since we did not see a direct correlation between the ra-
tio of Darpp-32:t-Darpp and tumor size.
We also saw variable expression of each protein from
tumor to tumor, similar to what is observed in humans
[3]. Expression did not seem to correlate with tumor lo-
cation or size. This could be a product of tumor hetero-





























PyMT/Ppp1r1b-/- (Tumor 4)PyMT/Ppp1r1b+/+ (Tumor 3)
Figure 4 Darpp-32 and t-Darpp expression in Ppp1r1b knockout mice. (A) Western analysis of Darpp-32 and t-Darpp protein levels in brain
tissue from wild-type (Ppp1r1b+/+) and knockout (Ppp1r1b-/-) mice. α–Tubulin was used as a loading control. (B) Mammary pads (abdominal and
inguinal, #4/5) were collected from 20-week-old Ppp1r1b+/+ and Ppp1r1b-/- mice. Formalin-fixed sections were stained for Darpp-32 (5× magnification,
scale bar = 200 μm). Black arrows indicate mammary epithelial cells surrounded by the adipose tissue of the mammary fat pad. (C) Western analysis of
Darpp-32 and t-Darpp protein levels in mammary tumor tissue. α–Tubulin was used as a loading control. All ten tumors were collected from 20-week-
old wild-type (PyMT/Ppp1r1b+/+) and knockout (PyMT/Ppp1r1b-/-) mice carrying the MMTV-PyMT transgene. Tumor samples are arranged from smallest
to largest (tumor volume) and the tumor location is specified. SKBR3 human breast cancer cells were used as a reference for Darpp-32 and
t-Darpp expression. (D) Mammary tumor samples were formalin-fixed and serial sections were stained for Darpp-32 and PyMT (5× magnification in a 6 × 6
tile, scale bar = 2000 μm; images enlarged from the boxed regions are at 10× magnification, scale bar = 200 μm). Tumor numbers correspond
to the numbering in panel C.
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There is little to no information on the transcriptional
regulation of Darpp-32 and t-Darpp. It will be interest-
ing to determine what regulates expression from one
promoter versus the other, perhaps as an initiating event
in tumorigenesis when transcription from the down-
stream t-Darpp promoter is pronounced.
One possibility, given the presence of a CpG island
within the first exon of Darpp-32, is that Darpp-32 is
down-regulated by tumor-specific hypermethylation,
thus permitting transcription from the downstream t-
Darpp promoter. Such expression would be expected to
promote growth and cell survival, thus perhaps contrib-
uting to tumorigenesis. Consistent with this idea, wehave data from human breast cell lines indicating that
the Darpp-32 promoter is in fact subject to silencing
through hypermethylation in malignant versus non-
malignant cells (unpublished observations). The shift in
expression from an absence of t-Darpp in healthy tissue
toward a predominance of t-Darpp in tumor tissue fur-
ther supports this theory. That Darpp-32 is sometimes
co-expressed with t-Darpp in malignant tissue suggests
that silencing is incomplete or that DNA methylation is
only one of several mechanisms responsible for regulat-
ing gene expression.
Because Darpp-32 and t-Darpp were jointly knocked
out in this mouse model, interpretation of the data is
somewhat difficult. Nevertheless, our results with Ppp1r1b
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promoting tumor growth. We observed lower overall
tumor volume in PyMT/Ppp1r1b-/- mice at 20 weeks of
age and trends toward delayed tumor appearance in these







































































































































































Figure 5 (See legend on next page.)a role predominant to Darpp-32 in mammary tumor de-
velopment. In normal mammary tissue, Darpp-32 might
have a type of tumor suppressor effect, whereas the de-
crease in Darpp-32 and gain of t-Darpp expression during

























































































(See figure on previous page.)
Figure 5 Tumor growth in PyMT/Ppp1r1b+/+ and PyMT/Ppp1r1b-/- mice. (A) The age at which tumors first appeared (tumor volume 100–300
mm3) was recorded for wild-type (PyMT/Ppp1r1b+/+) and knockout (PyMT/Ppp1r1b-/-) tumor mice (n = 14 per group). Individual ages and the mean
age at appearance (±standard error of the mean) are shown. (B) Kaplan–Meier survival plot showing the age at which mice were euthanized because
of extensive tumor burden (maximum tumor volume >1500 mm3). (C-D) Mice surviving to 20 weeks of age were euthanized and tumor volume was
measured. (C) Total tumor volume in these mice was calculated as the sum of the individual tumor volumes for each mouse. (D) Maximum
tumor volume was defined as the volume of the largest individual tumor per mouse (n = 8–12 per group); mean ± standard error of the mean,
*p < 0.05. (E-F) Tumors were collected at 20 weeks of age, formalin-fixed, sectioned and immuno-stained for Ki67 and CD31. (E) Representative tumor
sections and bar graph showing the mean (± standard error of the mean) number of Ki67-positive cells per field in 10 nonoverlapping fields from three
tumors per group (25× magnification, scale bar = 50 μm). (F) Representative tumor sections and bar graph showing the mean (± standard error of the
mean) microvessel density determined by counting the number of CD31-positive endothelial clusters (white arrows) in 10 nonoverlapping fields from
three tumors per group (25× magnification, scale bar = 50 μm). (G) Number of PyMT-positive metastatic nodules in each lung analyzed at 20 weeks of
age. Individual lung counts (n = 8 per group) and the mean (± standard error of the mean) for each genotype group are shown.
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beit at low levels, and this expression was almost always
accompanied by t-Darpp expression. This might offset any
tumor suppressor effects that Darpp-32 has in tumor tis-
sue. Indeed if Darpp-32 and t-Darpp have antagonistic ef-
fects on malignant cell growth, as we and others have
suggested [4-8,15], then knocking out both proteins could
potentially have a net neutral effect on tumor growth. This
might explain the lack of effect on steady-state Ki67
levels and the modest effects on tumor appearance and
volume that we observed. It will be interesting to see
how individual knockout of either Darpp-32 or t-Darpp
affects tumor development in either sporadic or PyMT-
driven tumorigenesis.
Another complicating factor originates with the
MMTV-PyMT tumor model used for these knockout ex-
periments. PyMT is a strong driver of cell proliferation
and tumors develop very quickly in 100% of mice. We ob-
served a median age of tumor initiation in PyMT/
Ppp1r1b+/+ mice of around 15 weeks, with some mice
reaching maximum tumor volume as early as 1–2 weeks
later. This might make it difficult to detect changes in
tumorigenesis or cell proliferation after knockout of a pos-
sible tumor suppressor (Darpp-32) or another tumor-
promoting protein (t-Darpp) in the PyMT background.
Moreover, rapid tumor development in MMTV-PyMT
mice does not allow much time for vascular and meta-
static development before mice reach maximum tumor
burden, thus complicating the investigation of these stages
in tumor progression. Looking at the effects of Ppp1r1b
knockout in a slower growing tumor model, such as the
MMTV-Neu model [23,24], might be helpful in elucidat-
ing the specific role of Ppp1r1b in both tumorigenesis and
the processes associated with metastasis.
In addition, larger sample sizes are likely needed to
gain a complete understanding of the role of Ppp1r1b in
metastasis. With only 80–94% of PyMT/Ppp1r1b+/+ mice
developing metastases [21], the sample size of eight mice
per group was likely too small to recognize anything but
very large differences in metastasis between PyMT/
Ppp1r1b+/+ and PyMT/Ppp1r1b-/- mice. It is perhapsnotable that a single PyMT/Ppp1r1b-/- female, with a total
of 22 lung metastases, inflated the PyMT/Ppp1r1b-/- group
average from 0.86 to 3.50 metastatic nodules per mouse,
thus skewing the metastasis data in this group of mice con-
siderably (Figure 5G). However, this outlier had little effect
on the statistical significance of the data given the variability
in metastases observed within each group. Interestingly,
this same mouse also had the largest total tumor volume
among the PyMT/Ppp1r1b-/- cohort. Larger tumor volume
did seem to be roughly associated with a higher number of
lung metastases (see Additional file 1: Figure S1C), so it is
not surprising that PyMT/Ppp1r1b-/- mice, with smaller
primary tumors, on average, would also have fewer lung
metastases than PyMT/Ppp1r1b+/+ mice. Taken together,
our data suggest a more important role for Ppp1r1b in af-
fecting tumor growth than metastasis per se, with t-Darpp
apparently having the predominant role to play. Others
have suggested that Darpp-32 acts to inhibit metastasis
[5,6], but again we might have missed such an effect with
the current model system in which both Darpp-32 and t-
Darpp are simultaneously knocked out.
Conclusions
The shift from Darpp-32 to t-Darpp during mouse
mammary tumorigenesis is reminiscent of the expres-
sion patterns observed in humans and is consistent
with the theorized opposing functions of t-Darpp and
Darpp-32 in promoting and inhibiting tumor progres-
sion, respectively. The data from the Ppp1r1b knockout
tumor mice suggest that the Ppp1r1b gene products, t-
Darpp in particular, could have a direct role in mammary
tumor development in MMTV-PyMT mice. Further in-
vestigation is needed, but it seems as though mouse mam-
mary tumor models could be a useful tool to better
understand the expression patterns and regulation of
Darpp-32 and t-Darpp in breast cancer.
Methods
Mice
Wild-type mice were provided by the City of Hope Ani-
mal Resources core facility. MMTV-Neu (strain FVB/N-Tg
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FVB/N-Tg(MMTV-PyVT)634Mul/J) [21,25] mice were
obtained from Jackson Laboratory (Bar Harbor, ME).
Darpp-32 (Ppp1r1b) knockout mice were kindly pro-
vided by Paul Greengard (The Rockefeller University,
New York, NY) [20]. Mouse breeding, monitoring for
tumor formation, and tissue collection and analysis are
described below. Mice were sacrificed for tissue and
tumor collection by CO2 inhalation. Experimental pro-
tocols were approved by the City of Hope Institutional
Animal Care and Use Committee (IACUC).
Cell culture
The mouse mammary epithelial cell line NMuMG was
kindly provided by Emily Wang (City of Hope, Duarte,
CA). NMuMG cells were maintained in DMEM with
10% FBS and 1% penicillin/streptomycin in 5% CO2.
The SKBR3 human breast cancer cell line was obtained
from the American Type Culture Collection (Rockville,
MD). SKBR3 cells were maintained in McCoy’s
Medium 5A with 10% FBS, 1% penicillin/streptomycin,
and 1% L-glutamine in 5% CO2.
Tissue collection
Brain tissue from sacrificed mice was extracted and frozen
in liquid nitrogen. Normal mammary pads (abdominal
and inguinal, #4/5 and #9/10) were resected and either
frozen whole in liquid nitrogen or immediately dissociated
for mammary cell isolation. Dissociation was conducted
using a Collagenase/Hyaluronidase dissociation solution
from Stem Cell Technologies (Vancouver, BC, Canada) ac-
cording to the manufacturer’s instructions. Briefly, mam-
mary pads were minced and incubated in the dissociation
solution at 37°C for 2 hours with frequent vortexing. After
centrifugation at 350 × g for 5 minutes, the supernatant
containing the liquefied fat tissue was discarded and the
mammary cells, enriched for epithelial cell organoids as
well as stromal cells and lymphocytes, were washed in
preparation for cell lysis and RNA isolation. For collection
of tumors, tumor length (L) and width (W) were measured
post-mortem (before dissection) using an electronic caliper.
Tumor volume (V) was calculated using the formula V =½
(L ×W2) [26,27]. Tumors were resected and immediately
frozen in liquid nitrogen. Frozen tissue was cut on dry ice
and homogenized in preparation for the isolation of cell
lysates and RNA.
Western analysis
Mouse tissue and cultured cell lysates were collected on
ice in RIPA buffer from Thermo Scientific (Waltham,
MA) supplemented with 1× protease inhibitor cocktail
from Roche Applied Science (Indianapolis, IN). Protein
concentration was determined by RC DC protein assay
purchased from Bio-Rad Laboratories (Hercules, CA).30 μg of protein from each sample was loaded onto a 12%
SDS-PAGE gel for protein separation and proteins were
transferred to a nitrocellulose membrane. 5% non-fat dry
milk was used for a blocking buffer and for primary anti-
body incubation. Primary antibodies included: an antibody
that recognizes both Darpp-32 and t-Darpp (#H62) from
Santa Cruz Biotechnology (Santa Cruz, CA) and anti-
bodies to α-Tubulin (#T5168) and β-Actin (#A4700) from
Sigma-Aldrich Corporation (St. Louis, MO). Secondary
antibodies were horseradish peroxidase-conjugated anti-
mouse IgG and anti-rabbit IgG antibodies from Cell Sig-
naling Technology (Danvers, Massachusetts). Secondary
antibody was detected using an ECL Plus kit from Thermo
Fisher Scientific. Protein expression was quantified using
ImageJ software and expressed as relative density, normal-
ized to loading control values. Mammary tissue was arbi-
trarily considered positive for protein expression when the
relative density was greater than 0.5.
RNA preparation and RT-PCR
Total RNA was isolated and purified using the Qiagen
RNeasy kit (Valencia, CA). Residual DNA was removed
from samples using the Ambion® TURBO DNA-free™
kit from Life Technologies (Carlsbad, CA). RNA was
reverse transcribed to cDNA using random primers
and SuperScript III Reverse Transcriptase from Life
Technologies. Darpp-32 and t-Darpp mRNA levels were
analyzed using either traditional or quantitative RT-PCR.
Traditional PCR (1 cycle of 30 sec at 98°C, 30 cycles of
30 sec at 98°C, 30 sec at 58°C, 15 sec at 72°C, and 5 min
incubation at 72°C) was performed using Finnzyme Phu-
sion Hot Start II DNA Polymerase from Thermo Scien-
tific. Quantitative RT-PCR (1 cycle of 3 min at 95°C,
40 cycles of 10 sec at 95°C, 30 sec at 58°C, and a melting
curve 55–95°C) was performed using the PerfeCTa® SYBR®
Green SuperMix from Quanta BioSciences (Gaithersburg,
MD). Quadruplicate measurements were made on a single
isolation of RNA from each sample analyzed. Primers
5′-AGATTCAGTTCTCTGTGCCCG-3′ and 5′-GGTT
CTCTGATGTGGAGAGGC-3′ were used to amplify
Darpp-32 mRNA; primers 5′-CGATGGTGAGGTGC
CCCTAT-3′ and 5′-CTCCTCTGGTGAGGAGTGCT-
3′ were used to amplify t-Darpp mRNA; and primers
5′-AGATCAAGATCATTGCTCCTCCC-3′ and 5′-AA
GGGTGTAAAACGCAGCTC-3′ were used to amplify
β-Actin mRNA.
In vivo tumorigenesis
Ppp1r1b knockout mice with a pure C57BL/6 back-
ground were crossed with MMTV-PyMT mice with a
50:50 mixed C57BL/6 and FVB background. To ensure
that all experimental mice contained the same back-
ground percentages of C57BL/6 and FVB (75:25, respect-
ively), F1 mice were back-crossed for two generations and
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DNA. Ppp1r1b+/+, Ppp1r1b-/-, PyMT/Ppp1r1b+/+ and
PyMT/Ppp1r1b-/- mice from the F3+ generation(s) were
used in all reported experiments. Starting at 8 weeks of
age, mice were monitored weekly for the appearance of
palpable tumors. A palpable tumor was defined as a tumor
with a volume between 100–300 mm3. Tumor volume
was measured weekly until mice were sacrificed at
20 weeks of age. Mice were sacrificed prior to 20 weeks of
age when a tumor reached a volume >1500 mm3 (in ac-
cordance with the approved IACUC protocol’s definition
of excessive tumor burden), and these mice were not in-
cluded in any of the 20-week data sets. A final measure of
tumor volume was taken post-mortem before tissue was
collected for molecular and pathological analysis. Total
tumor volume was calculated for each mouse as the sum
of the individual tumor volumes. Maximum tumor vol-
ume was defined as the volume of the largest individual
tumor in each mouse.Histology and immunohistochemistry
Lungs obtained from sacrificed mice were perfused
intra-tracheally and fixed in 10% buffered formalin. Tu-
mors and normal mammary pads (abdominal and in-
guinal, #4/5) were resected and fixed in 10% buffered
formalin. Tissues were paraffin embedded and sectioned
(5 μm thick). Serial sections were stained with
hematoxylin and eosin (H&E) and prepared for immu-
nohistochemical analysis. Slides were deparaffinized in
xylene followed by 100–70% ethanols, quenched in 3%
hydrogen peroxide and pretreated to promote antigen
retrieval with either a High pH or DIVA buffer. Slides
were then pretreated with a blocking serum and incu-
bated in primary antibody. Primary antibodies were: a
rabbit monoclonal antibody specific for Darpp-32
(#40801) from Abcam (Cambridge, MA) at 1:500 dilu-
tion in PBS for 30 min at room temperature (RT); a rat
monoclonal antibody specific for Polyoma virus medium
T antigen (PyMT, #NB-100-2749) from Novus Biologi-
cals LLC (Littleton, CO) at 1:300 dilution in PBS for
30 min at RT; a goat polyclonal antibody specific for
CD31/PECAM1 (#sc1506) from Santa Cruz Biotechnol-
ogy at 1:500 dilution in PBS for 30 min at RT; and a
rabbit polyclonal antibody specific for Ki67 (#PA5-
19462) from Thermo Scientific at 1:200 dilution in PBS
for 30 min at RT. Secondary antibodies were biotinylated
anti-rabbit (#BA-1000), anti-goat (#BA-9500) and anti-
rat (#BA-4001) from Vector Lab (Burlingame, CA), and
an anti-rabbit secondary polymer from Dako (#K4003,
Carpinteria, CA). Slides were then incubated with the
chromogen diaminobenzidine tetrahydrochloride, coun-
terstained with hematoxylin and mounted with a per-
manent mounting media.The histological and immunohistochemical results were
visually inspected by a veterinary pathologist while blinded
to the genotype of each specimen. All images were taken
using a Zeiss Axio Observer Z1 Inverted microscope with
a Hamamatsu EMCCD C9100-13 Monochromo camera
and Zeiss AxioVision 4.8 software. Tumors and mammary
pads were imaged using either the 5×/0.16NA Phan-
NeoFluar Phase objective (5× magnification in a 6 × 6 tile
on an automated stage) or the 10×/0.5NA Fluar DIC
objective (10× magnification). Ki67 and CD31 expression
in mammary tumors was imaged using the 25×/0.8NA
LCI PlanApo Multi Immersion DIC, Correction Collar,
LD objective (25× magnification). The number of Ki67-
positive cells was counted in 10 nonoverlapping fields in
three tumors per group [28]. Microvessel density was
quantified by counting the number of CD31-positive
endothelial clusters in 10 nonoverlapping fields in three
tumors per group (25× magnification) [28,29].
Lung metastasis
Lung sections stained with H&E (three sagittal sections
separated by 15 μm, cut from deep within each lung) were
visually examined for lung metastasis by a veterinary path-
ologist. Lung sections stained for PyMT expression were
scanned using a Zeiss Axio Observer Z1 Inverted micro-
scope with a Hamamatsu EMCCD C9100-13 Mono-
chromo camera and 5×/0.16NA Phan-NeoFluar Phase
objective using Zeiss AxioVision 4.8 software (5× magnifi-
cation in a 5 × 10 tile on an automated stage). Image Pro
Premier 9.0 imaging software was used to count the total
number of PyMT-positive metastatic lung nodules per
mouse and to measure the area of each nodule to deter-
mine their classification as either a micrometastasis
(≤0.025 mm2) or a macrometastasis (>0.025 mm2).
Statistical analysis
Statistically significant differences were calculated using
the GraphPad Prism 6.0 statistical program. Differences
between groups were determined by the two-tailed
Student’s t-test, and Kaplan-Meier plots of survival
were analyzed using the log-rank Mantel Cox test. p
values <0.05 were considered significant.
Additional file
Additional file 1: Figure S1. Lung metastasis. Lung tissue was collected at
20 weeks of age and examined for metastasis. (A) Formalin-fixed lungs were
sectioned and stained with H&E and for PyMT expression (5× magnification in
a 4 × 9 tile, scale bar = 2000 μm). The boxed regions are shown as enlarged
images in the bottom panels (5× magnification in a 2 × 3 tile, scale bar = 500
μm). These highlight the differences between micrometastases (white arrows,
≤0.025 mm2) and macrometastases (black arrows, >0.25 mm2). (B) The
number of PyMT-positive micro- and macrometastases in each lung were
counted (n = 8 per group); mean ± standard error of the mean. (C) The
relationship between tumor volume and metastases, including the Pearson
correlation coefficient and best fit linear regression.
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